Carl Denny Email

VP - Head Regulatory Affairs . Abeona Therapeutics

Current Roles

Employees:
96
Revenue:
$5.3M
About
Abeona Therapeutics Inc.(NASDAQ: $ABEO)is a leading clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening rare genetic diseases. Abeona's lead programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV-NAGLU), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type B (MPS IIIB). Abeona is also developing ABO-201 (AAV-CLN3) gene therapy for CLN3 disease, ABO-202 (AAV-CLN1) for treatment of CLN1 disease, EB-201 for epidermolysis bullosa (EB), ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. In addition, Abeona is developing a proprietary vector platform, AIM, for next generation product candidates. For more information, visit www.abeonatherapeutics.com.
Abeona Therapeutics Address
1330 Avenue of the America
New York, NY
United States

Past Companies

Abeona TherapeuticsVice President - Head of Regulatory Affairs
Sarepta TherapeuticsExecutive Director - Regulatory Strategy
AveXis, Inc.Sr. Director - US Regulatory Affairs at AveXis, Inc.

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.